Oxiracetam In The Treatment Of Multi-infarct Dementia
| Effect | Decrease |
| Trial Design | Non-controlled trial |
| Trial Length | 1-6 months |
| Number of Subjects | 12 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
12 weeks supplementation of oxiracetam (400mg for 4 weeks, building up to 1,200mg for 4 weeks) was able to provide a modest improvement on clinical ratings of cognition by about 1 point (on a 5 point scale) and seemed to favor verbal improvements.
